BTG To Initiate Target Study To Evaluate Dosimetry For HCC Patients

BTG plc (BTG) said it plans to initiate the TheraSphere Advanced Dosimetry Retrospective Global Study Evaluation in Hepatocellular Carcinoma Treatment, or TARGET.

from RTT - Biotech http://ift.tt/22XCFly
via IFTTT